13 completed, 6 recruiting, 3 active not recruiting, 3 terminated. 28 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 13, Recruiting 6, Active not recruiting 3, Terminated 3, Not yet recruiting 2, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Terminated 1 |
Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy α-Syn H21 Monoclonal Antibody - Multiple System Atrophy | Phase 1 | Not yet recruiting | Ruijin Hospital | 3 | 2026-09-15 | 2026-08-19 |
| A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA SST001 - Multiple System Atrophy (MSA), Parkinson's Disease (PD) | Phase 1 | Recruiting | Synusight Biotech (Shanghai) Co., Ltd. | 30 | 2026-06-15 | 2026-09-01 |
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic | Phase 1 / Phase 2 | Recruiting | Julien Bally | 36 | 2025-07-18 | 2026-01-29 |
| hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases hUC-MSC-sEV-001 nasal drops - Alzheimer Disease, Parkinson Disease | Phase 1 | Not yet recruiting | Xuanwu Hospital, Beijing | 120 | 2025-07-01 | 2025-07-08 |
| Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies Sural Nerve Graft to the Substantia Nigra, Sham surgery - Multiple System Atrophy, Parkinsons Disease | Phase 1 | Recruiting | Craig van Horne, MD, PhD | 7 | 2025-02-25 | 2026-08-31 |
| GDNF Gene Therapy for Multiple System Atrophy AAV2-GDNF gene therapy, Sham (Placebo) Surgery - Multiple System Atrophy | Phase 1 | Active not recruiting | Brain Neurotherapy Bio, Inc. | 9 | 2023-10-03 | 2026-01-30 |
| UB-312 in Patients With Synucleinopathies UB-312 Injection, Placebo Injection - Multiple System Atrophy, Parkinson Disease | Phase 1 | Completed | NYU Langone Health | 8 | 2023-05-31 | 2026-03-16 |
| Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID stellate ganglion block with 0.5% bupivacaine - Post Acute COVID-19 Syndrome, Long COVID | Phase 1 | Completed | Jonathann Kuo, MD | 20 | 2023-01-03 | 2025-03-13 |
| Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA) hOMSC300 - Multiple System Atrophy, MSA - Multiple System Atrophy | Phase 1 | Active not recruiting | Cytora Ltd. | 10 | 2022-11-07 | 2025-01-29 |
| A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 54 | 2022-09-12 | 2023-03-23 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) ION464, Placebo - Multiple System Atrophy | Phase 1 | Recruiting | Ionis Pharmaceuticals, Inc. | 40 | 2022-07-21 | 2026-04-27 |
| Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein [18F]UCB-2897 - Parkinson Disease, Multisystem Atrophy | Phase 1 | Completed | Invicro | 5 | 2022-01-31 | 2025-02-20 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease anle138b, Placebo - Parkinson Disease | Phase 1 | Completed | MODAG GmbH | 70 | 2020-12-22 | 2023-03-22 |
| [18F]F-DOPA Imaging in Patients With Autonomic Failure [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose - Autonomic Failure, Pure Autonomic Failure | Phase 1 | Recruiting | Daniel Claassen | 40 | 2020-02-04 | 2026-03-16 |
| A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects anle138b, Placebo - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 68 | 2019-12-06 | 2020-08-06 |
| Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy CS10BR05 - Multiple System Atrophy | Phase 1 | Completed | Corestemchemon, Inc. | 9 | 2018-04-13 | 2024-10-18 |
| Automated Abdominal Binder for Orthostatic Hypotension automated abdominal binder, Sham binder, Placebo - Orthostatic Hypotension, Autonomic Failure | Phase 1 / Phase 2 | Completed | Vanderbilt University Medical Center | 28 | 2018-03-01 | 2026-05-05 |
| Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Droxidopa, Midodrine, Placebo - Autonomic Failure, Pure Autonomic Failure | Phase 1 | Terminated | Vanderbilt University Medical Center | 34 | 2016-09-01 | 2026-10-23 |
| Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Trimethaphan, Placebo - Multiple System Atrophy, Orthostatic Hypotension | Phase 1 | Active not recruiting | Vanderbilt University | 2 | 2016-04-01 | 2026-03-13 |
Showing 20 of 28. Sign in to see all of them.
Parkinson Disease (14) · Pure Autonomic Failure (8) · Hypotension, Orthostatic (5) · Shy-Drager Syndrome (5) · Alzheimer Disease (4) · Hypertension (4) · Neurodegenerative Diseases (4) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Tauopathies (3) · Autonomic Nervous System Diseases (2) · Lewy Body Disease (2) · Amyotrophic Lateral Sclerosis (1) · COVID-19 (1) · Dysautonomia like disorder (1)
Basal Ganglia Diseases (28) · Brain Diseases (28) · Central Nervous System Diseases (28) · Movement Disorders (28) · Nervous System Diseases (28) · Primary Dysautonomias (28) · Autonomic Nervous System Diseases (26) · Synucleinopathies (25) · Neurodegenerative Diseases (22) · Parkinsonian Disorders (14) · Cardiovascular Diseases (12) · Vascular Diseases (12) · Hypotension (10) · Dementia (5) · Mental Disorders (5)
3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (3) · Carbidopa (3) · Midodrine (3) · Captopril (2) · Droxidopa (2) · Losartan (2) · Sodium Chloride (2) · Trimethaphan (2) · entacapone (2) · Adjuvants, Pharmaceutic (1) · Arginine (1) · Aspirin (1) · Aspirin, Dipyridamole Drug Combination (1) · Bosentan (1) · Bupivacaine (1)
Vanderbilt University (5) · MODAG GmbH (3) · Vanderbilt University Medical Center (3) · Affiris AG (1) · Brain Neurotherapy Bio, Inc. (1) · Corestemchemon, Inc. (1) · Craig van Horne, MD, PhD (1) · Cytora Ltd. (1) · Daniel Claassen (1) · Invicro (1) · Ionis Pharmaceuticals, Inc. (1) · Jonathann Kuo, MD (1) · Julien Bally (1) · NYU Langone Health (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (16) · United Kingdom (4) · China (3) · France (2) · Australia (1) · Austria (1) · Germany (1) · Israel (1) · Portugal (1) · South Korea (1) · Switzerland (1)
Italo Biaggioni, MD (6) · Italo Biaggioni, M.D. (2) · Luis E Okamoto, MD (2) · Nand Singh, BSc, MD, DPM, MFPM (2) · Amy Knorr, MD (1) · Craig van Horne, MD, PhD (1) · David Russell, MD, Ph.D (1) · David S Goldstein, M.D. (1) · Horacio Kaufmann, MD (1) · Jonathan Evans, MD (1) · Jonathann Kuo, MD (1) · Joyce Gibbons, PA-C (1) · Kerrie Schoffer, MBBS (1) · Nand Singh, MD (1) · Phil Hyu Lee, M.D. (1)
PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16391172, PMID 16533484, PMID 17116758, PMID 18426998, PMID 19047577, PMID 19738158, PMID 22469621, PMID 22801444, PMID 23266540, PMID 27153166, PMID 29451447, PMID 32882100, PMID 34000076, PMID 35500536, PMID 35949912, PMID 9369256, PMID 9890307
2019 (2), R01HL144568 (2), 2014 (1), UL1TR001998 (1)